A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Fulvestrant (Primary) ; GSK 525762 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Jun 2017 Planned primary completion date changed from 23 Apr 2020 to 29 Mar 2019.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 May 2017 Planned End Date changed from 13 Jun 2022 to 1 Jun 2020.